| ￥2800 | |
| Z05375-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 0.1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized HGF, His, Human at 2μg/ml (100μl/Well) on the plate can bind Human HGF R, hFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 79.6 kDa (after cleavage of the signal peptide) | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 60-65 kDa and 30-40 kDa corresponding to α chain and β chain based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS, 200mM L-arginine (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Hepatocyte growth factor (HGF) is an important component of the pathophysiology of IR, with increased levels in most common IR conditions, including obesity. HGF has a role in the metabolic flux of glucose in different insulin sensitive cell types. |
| Synonyms | Hepatopoietin-A; SF; HPTA; HGF; DFNB39; F-TCF; F-TCFB; HGFB |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
